Antibody glycosylation: impact on antibody drug characteristics and quality control

  • 69 Accesses


Glycosylation is a common post-translational modification that occurs during the production of antibodies. Glycans attached to antibodies play an important role in the pharmacokinetics, efficacy, and safety of therapeutic antibodies. In the modern antibody industry, it is important to adjust and control glycosylation modifications. The formation of specific sugar structures via glycosylation engineering is constantly evolving. This review summarizes the recent progress in glycosylation modifications, as well as the major discoveries and current understanding of the mechanisms involved, to provide new ideas for the research and development of therapeutic antibodies.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.


  1. Adamczyk B, Tharmalingam-Jaikaran T, Schomberg M, Szekrenyes A, Kelly RM, Karlsson NG, Guttman A, Rudd PM (2014) Comparison of separation techniques for the elucidation of IgG N-glycans pooled from healthy mammalian species. Carbohydr Res 389:174–185.

  2. Aghamohseni H, Ohadi K, Spearman M, Krahn N, Moo-Young M, Scharer JM, Butler M, Budman HM (2014) Effects of nutrient levels and average culture pH on the glycosylation pattern of camelid-humanized monoclonal antibody. J Biotechnol 186:98–109.

  3. Alisson-Silva F, Kawanishi K, Varki A (2016) Human risk of diseases associated with red meat intake: analysis of current theories and proposed role for metabolic incorporation of a non-human sialic acid. Mol Asp Med 51:16–30.

  4. Azadi P, Heiss C (2009) Mass spectrometry of N-linked glycans. Methods Mol Biol 534:37–51.

  5. Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM (2008) Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res 36(15):e96.

  6. Barallobre-Barreiro J, Baig F, Fava M, Yin X, Mayr M (2017) Glycoproteomics of the extracellular matrix: a method for intact glycopeptide analysis using mass spectrometry. J Vis Exp 122.

  7. Bas M, Terrier A, Jacque E, Dehenne A, Pochet-Beghin V, Beghin C, Dezetter AS, Dupont G, Engrand A, Beaufils B, Mondon P, Fournier N, de Romeuf C, Jorieux S, Fontayne A, Mars LT, Monnet C (2019) Fc Sialylation prolongs serum half-life of therapeutic antibodies. J Immunol 202(5):1582–1594.

  8. Behnken HN, Ruthenbeck A, Schulz JM, Meyer B (2014) Glycan analysis of prostate specific antigen (PSA) directly from the intact glycoprotein by HR-ESI/TOF-MS. J Proteome Res 13(2):997–1001.

  9. Billioud V, Sandborn WJ, Peyrin-Biroulet L (2011) Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 106(4):674–684.

  10. Bloem K, Vuist IM, Plas AJVD, Knippels LMJ, Garssen J, Garcíavallejo JJ, Vliet SJV, Kooyk YV (2013) Ligand binding and signaling of dendritic cell immunoreceptor (DCIR) is modulated by the glycosylation of the carbohydrate recognition domain. PLoS One 8(6):e66266

  11. Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G (2012) Revisiting the role of glycosylation in the structure of human IgG fc. ACS Chem Biol 7(9):1596–1602.

  12. Brightbill H, Lin Y, Lin Z, Tan M, Meng Y, Balazs M, Chung S, Wu L (2014) Quilizumab is an afucosylated humanized anti-M1 prime therapeutic antibody. Clin Anti-Inflamm Anti-Allerg Drug 1(1):24–31.

  13. Buettner MJ, Shah SR, Saeui CT, Ariss R, Yarema KJ (2018) Improving immunotherapy through glycodesign. Front Immunol 9:2485.

  14. Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SR, Delahunty CM, McLellan JS, Burton DR, Yates JR, Paulson JC (2018) Global site-specific analysis of glycoprotein N-glycan processing. Nat Protoc 13(6):1196–1212.

  15. Cao L, Zhang Y, Chen L, Shen A, Zhang X, Ren S, Gu J, Yu L, Liang X (2014) Sample preparation for mass spectrometric analysis of human serum N-glycans using hydrophilic interaction chromatography-based solid phase extraction. Analyst 139(18):4538–4546.

  16. Chen WC, Murawsky CM (2018) Strategies for generating diverse antibody repertoires using transgenic animals expressing human antibodies. Front Immunol 9:460.

  17. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358(11):1109–1117.

  18. Chung CY, Wang Q, Yang S, Yin B, Zhang H, Betenbaugh M (2017) Integrated genome and protein editing swaps alpha-2,6 sialylation for alpha-2,3 Sialic acid on recombinant antibodies from CHO. Biotechnol J 12(2).

  19. Cymer F, Beck H, Rohde A, Reusch D (2018) Therapeutic monoclonal antibody N-glycosylation - structure, function and therapeutic potential. Biologicals 52:1–11.

  20. Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T (2015) Multi-angle effector function analysis of human monoclonal IgG glycovariants. PLoS One 10(12):e0143520.

  21. Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, Matlung H, van den Berg TK, van Esch WJE, Kuijpers TW, Wouters D, Rispens T, Wuhrer M, Vidarsson G (2017) Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of fc-receptor- and complement-mediated-effector activities. Front Immunol 8:877.

  22. Dotz V, Haselberg R, Shubhakar A, Kozak RP, Falck D, Rombouts Y, Reusch D, Somsen GW, Fernandes DL, Wuhrer M (2015) Mass spectrometry for glycosylation analysis of biopharmaceuticals. Trac-Trend Anal Chem 73:1–9.

  23. Eschwege V, Yelnik CM, Zuily S, Wahl D (2018) Brief report on the 10th meeting of the European forum on antiphospholipid antibodies. Curr Rheumatol Rep 20(10) doi:ARTN 63

  24. Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93(5):851–861.

  25. Gao B, Long C, Lee W, Zhang Z, Gao X, Landsittel D, Ezzelarab M, Ayares D, Huang Y, Cooper DKC, Wang Y, Hara H (2017) Anti-Neu5Gc and anti-non-Neu5Gc antibodies in healthy humans. PLoS One 12(7):e0180768.

  26. Garcia-Aguilar T, Espinosa-Cueto P, Magallanes-Puebla A, Mancilla R (2016) The mannose receptor is involved in the phagocytosis of mycobacteria-induced apoptotic cells. J Immunol Res 2016:3845247.

  27. Geyer H, Geyer R (2006) Strategies for analysis of glycoprotein glycosylation. Biochim Biophys Acta 1764(12):1853–1869.

  28. Giddens JP, Wang LX (2015) Chemoenzymatic glyco-engineering of monoclonal antibodies. Methods Mol Biol 1321:375–387.

  29. Gisbert JP, Panes J (2009) Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 104(3):760–767.

  30. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC (2011) High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21(7):949–959.

  31. Gong Q, Hazen M, Marshall B, Crowell SR, Ou Q, Wong AW, Phung W, Vernes JM, Meng YG, Tejada M, Andersen D, Kelley RF (2016) Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation. MAbs 8(6):1098–1106.

  32. Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, Priem P, van den Bremer ET, Gerritsen J, van Berkel PH (2011) Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng 108(7):1591–1602.

  33. Ha S, Wang Y, Rustandi RR (2011) Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris. MAbs 3(5):453–460.

  34. Hayes JM, Frostell A, Karlsson R, Muller S, Martin SM, Pauers M, Reuss F, Cosgrave EF, Anneren C, Davey GP, Rudd PM (2017) Identification of Fc gamma receptor glycoforms that produce differential binding kinetics for rituximab. Mol Cell Proteomics 16(10):1770–1788.

  35. Higel F, Seidl A, Sorgel F, Friess W (2016) N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and fc fusion proteins. Eur J Pharm Biopharm 100:94–100.

  36. Hodoniczky J, Zheng YZ, James DC (2010) Control of recombinant monoclonal antibody effector functions by fc N -glycan remodeling in vitro. Biotechnol Prog 21(6):1644–1652

  37. Hristodorov D, Fischer R, Joerissen H, Muller-Tiemann B, Apeler H, Linden L (2013) Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol Biotechnol 53(3):326–335.

  38. Hurtado-Guerrero R, Davies GJ (2012) Recent structural and mechanistic insights into post-translational enzymatic glycosylation. Curr Opin Chem Biol 16(5–6):479–487.

  39. Janinbussat MC, Tonini L, Huillet C, Colas O, Klinguerhamour C, Corvaïa N, Beck A (2013) Cetuximab fab and fc N-glycan fast characterization using IdeS digestion and liquid chromatography coupled to electrospray ionization mass spectrometry. Methods Mol Biol 988:93

  40. Jefferis R (2009) Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30(7):356–362.

  41. Jennewein MF, Alter G (2017) The immunoregulatory roles of antibody glycosylation. Trends Immunol 38(5):358–372.

  42. Kelly RM, Kowle RL, Lian Z, Strifler BA, Witcher DR, Parekh BS, Wang T, Frye CC (2018) Modulation of IgG1 immunoeffector function by glycoengineering of the GDP-fucose biosynthesis pathway. Biotechnol Bioeng 115(3):705–718.

  43. Klapoetke S, Zhang J, Becht S, Gu X, Ding X (2010) The evaluation of a novel approach for the profiling and identification of N-linked glycan with a procainamide tag by HPLC with fluorescent and mass spectrometric detection. J Pharm Biomed Anal 53(3):315–324.

  44. Kozak RP, Tortosa CB, Fernandes DL, Spencer DI (2015) Comparison of procainamide and 2-aminobenzamide labeling for profiling and identification of glycans by liquid chromatography with fluorescence detection coupled to electrospray ionization-mass spectrometry. Anal Biochem 486:38–40.

  45. Kurogochi M, Mori M, Osumi K, Tojino M, Sugawara S, Takashima S, Hirose Y, Tsukimura W, Mizuno M, Amano J, Matsuda A, Tomita M, Takayanagi A, Shoda S, Shirai T (2015) Glycoengineered monoclonal antibodies with homogeneous glycan (M3, G0, G2, and A2) using a chemoenzymatic approach have different affinities for FcgammaRIIIa and variable antibody-dependent cellular cytotoxicity activities. PLoS One 10(7):e0132848.

  46. Kussmann M, Nordhoff E, RahbekNielsen H, Haebel S, RosselLarsen M, Jakobsen L, Gobom J, Mirgorodskaya E, KrollKristensen A, Palm L, Roepstorff P (1997) Matrix-assisted laser desorption/ionization mass spectrometry sample preparation techniques designed for various peptide and protein analytes. J Mass Spectrom 32(6):593–601

  47. Lauber MA, Yu YQ, Brousmiche DW, Hua Z, Koza SM, Magnelli P, Guthrie E, Taron CH, Fountain KJ (2015) Rapid preparation of released N-Glycans for HILIC analysis using a labeling reagent that facilitates sensitive fluorescence and ESI-MS detection. Anal Chem 87(10):5401–5409.

  48. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, Risteli L, Lee YC, Feizi T, Langen H, Nussenzweig MC (2002) Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 295(5561):1898–1901.

  49. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, Bobrowicz P, Choi BK, Cook WJ, Cukan M, Houston-Cummings NR, Davidson R, Gong B, Hamilton SR, Hoopes JP, Jiang Y, Kim N, Mansfield R, Nett JH, Rios S, Strawbridge R, Wildt S, Gerngross TU (2006) Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24(2):210–215.

  50. Li TJ, Cheng JR, Hu BS, Liu Y, Qian GL, Liu FQ (2008) Construction, production, and characterization of recombinant scFv antibodies against methamidophos expressed in Pichia pastoris. World J Microb Biot 24(6):867–874.

  51. Lisacek F, Mariethoz J, Alocci D, Rudd PM, Abrahams JL, Campbell MP, Packer NH, Ståhle J, Widmalm G, Mullen E, Adamczyk B, Rojas-Macias MA, Jin C, Karlsson NG (2017) Databases and associated tools for glycomics and glycoproteomics. In: Lauc G, Wuhrer M (eds) High-throughput glycomics and glycoproteomics: methods and protocols. Springer New York, New York, NY, pp 235–264

  52. Liu CP, Tsai TI, Cheng T, Shivatare VS, Wu CY, Wu CY, Wong CH (2018a) Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation. Proc Natl Acad Sci U S A 115(4):720–725.

  53. Liu CP, Tsai TI, Cheng T, Shivatare VS, Wu CY, Wu CY, Wong CH (2018b) Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation. Proc Natl Acad Sci U S A 115(4):720–725.

  54. Liu L, Gomathinayagam S, Hamuro L, Prueksaritanont T, Wang W, Stadheim TA, Hamilton SR (2013) The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia Pastoris. Pharm Res 30(3):803–812.

  55. Lubbers J, Rodriguez E, van Kooyk Y (2018) Modulation of immune tolerance via siglec-sialic acid interactions. Front Immunol 9:2807.

  56. Luo C, Chen S, Xu N, Wang C, Sai WB, Zhao W, Li YC, Hu XJ, Tian H, Gao XD, Yao WB (2017) Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties. Sci Rep 7:46347.

  57. Macher BA, Galili U (2008) The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 1780(2):75–88.

  58. Maier M, Reusch D, Bruggink C, Bulau P, Wuhrer M, Molhoj M (2016) Applying mini-bore HPAEC-MS/MS for the characterization and quantification of Fc N-glycans from heterogeneously glycosylated IgGs. J Chromatogr B Analyt Technol Biomed Life Sci 1033-1034:342–352.

  59. Melmer M, Stangler T, Schiefermeier M, Brunner W, Toll H, Rupprechter A, Lindner W, Premstaller A (2010) HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals. Anal Bioanal Chem 398(2):905–914.

  60. Mimura Y, Kelly RM, Unwin L, Albrecht S, Jefferis R, Goodall M, Mizukami Y, Mimura-Kimura Y, Matsumoto T, Ueoka H, Rudd PM (2016) Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines. J Immunol Methods 428:30–36.

  61. Muthing J, Kemminer SE, Conradt HS, Sagi D, Nimtz M, Karst U, Peter-Katalinic J (2003) Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol Bioeng 83(3):321–334.

  62. Nilsson J (2016) Liquid chromatography-tandem mass spectrometry-based fragmentation analysis of glycopeptides. Glycoconj J 33(3):261–272.

  63. Nimmerjahn F, Anthony RM, Ravetch JV (2007) Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A 104(20):8433–8437.

  64. Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513–533.

  65. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol 336(5):1239–1249.

  66. Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, Chen X, Varki A (2008) Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 18(10):818–830.

  67. Peschke B, Keller CW, Weber P, Quast I, Lunemann JD (2017) Fc-Galactosylation of human immunoglobulin gamma Isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol 8:646.

  68. Plomp R, Dekkers G, Rombouts Y, Visser R, Koeleman CA, Kammeijer GS, Jansen BC, Rispens T, Hensbergen PJ, Vidarsson G (2015) Hinge-region O-Glycosylation of human immunoglobulin G3 (IgG3). Mol Cell Proteomics 14(5):1373–1384

  69. Purcell O, Opdensteinen P, Chen W, Lowenhaupt K, Brown A, Hermann M, Cao J, Tenhaef N, Kallweit E, Kastilan R, Sinskey AJ, Perez-Pinera P, Buyel JF, Lu TK (2017) Production of functional anti-Ebola antibodies in Pichia pastoris. ACS Synth Biol 6(12):2183–2190.

  70. Purohit S, Li T, Guan W, Song X, Song J, Tian Y, Li L, Sharma A, Dun B, Mysona D, Ghamande S, Rungruang B, Cummings RD, Wang PG, She JX (2018) Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins. Nat Commun 9(1):258.

  71. Qu Y, Sun L, Zhang Z, Dovichi NJ (2018a) Site-specific glycan heterogeneity characterization by hydrophilic interaction liquid chromatography solid-phase extraction, reversed-phase liquid chromatography fractionation, and capillary zone electrophoresis-electrospray ionization-tandem mass spectrometry. Anal Chem 90(2):1223–1233.

  72. Qu Y, Sun L, Zhu G, Zhang Z, Peuchen EH, Dovichi NJ (2018b) Sensitive and fast characterization of site-specific protein glycosylation with capillary electrophoresis coupled to mass spectrometry. Talanta 179:22–27.

  73. Raju TS, Briggs JB, Borge SM, Jones AJ (2000) Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10(5):477–486

  74. Raju TS, Jordan RE (2012) Galactosylation variations in marketed therapeutic antibodies. MAbs 4(3):385–391.

  75. Ravindranath MH, Jucaud V, Ferrone S (2018) Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: evaluation of beadsets from different manufacturers (vol 450, pg 73, 2017). J Immunol Methods 460:125–125.

  76. Reusch D, Haberger M, Maier B, Maier M, Kloseck R, Zimmermann B, Hook M, Szabo Z, Tep S, Wegstein J, Alt N, Bulau P, Wuhrer M (2015) Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods. MAbs 7(1):167–179.

  77. Reusch D, Tejada ML (2015) Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 25(12):1325–1334.

  78. Ruhaak LR, Zauner G, Huhn C, Bruggink C, Deelder AM, Wuhrer M (2010) Glycan labeling strategies and their use in identification and quantification. Anal Bioanal Chem 397(8):3457–3481.

  79. Samraj AN, Bertrand KA, Luben R, Khedri Z, Yu H, Nguyen D, Gregg CJ, Diaz SL, Sawyer S, Chen X, Eliassen H, Padler-Karavani V, Wu K, Khaw KT, Willett W, Varki A (2018) Polyclonal human antibodies against glycans bearing red meat-derived non-human sialic acid N-glycolylneuraminic acid are stable, reproducible, complex and vary between individuals: total antibody levels are associated with colorectal cancer risk. PLoS One 13(6):e0197464.

  80. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44(7):1524–1534.

  81. Scholler N, Garvik B, Quarles T, Jiang S, Urban N (2006) Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods 317(1–2):132–143.

  82. Sengupta PP, Rudramurthy GR, Ligi M, Jacob SS, Rahman H, Roy P (2018) Development and evaluation of recombinant antigen and monoclonal antibody based competition ELISA for the sero-surveillance of surra in animals. J Immunol Methods 460:87–92.

  83. Seo JS, Kim YJ, Cho JM, Baek E, Lee GM (2013) Effect of culture pH on recombinant antibody production by a new human cell line, F2N78, grown in suspension at 33.0 degrees C and 37.0 degrees C. Appl Microbiol Biotechnol 97(12):5283–5291.

  84. Seo JS, Min BS, Kim YJ, Cho JM, Baek E, Cho MS, Lee GM (2014) Effect of glucose feeding on the glycosylation quality of antibody produced by a human cell line, F2N78, in fed-batch culture. Appl Microbiol Biotechnol 98(8):3509–3515.

  85. Shaheen HH, Prinz B, Chen MT, Pavoor T, Lin S, Houston-Cummings NR, Moore R, Stadheim TA, Zha D (2013) A dual-mode surface display system for the maturation and production of monoclonal antibodies in glyco-engineered Pichia pastoris. PLoS One 8(7):e70190.

  86. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278(5):3466–3473.

  87. Smith SL (1996) Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 6(3):109

  88. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F (2008) Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 8(14):2858–2871.

  89. Steinke JW, Platts-Mills TA, Commins SP (2015) The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 135(3):589–596; quiz 597.

  90. Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, Mach L, Glossl J, Weterings K, Pabst M, Steinkellner H (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 6(4):392–402.

  91. Subramaniam JM, Whiteside G, McKeage K, Croxtall JC (2012) Mogamulizumab. Drugs 72(9):1293–1298.

  92. Sun T, Li CD, Han L, Jiang H, Xie YQ, Zhang BH, Qian XP, Lu HL, Zhu JW (2015) Functional knockout of FUT8 in Chinese hamster ovary cells using CRISPR/Cas9 to produce a defucosylated antibody. Eng Life Sci 15(6):660–666.

  93. Szabo Z, Guttman A, Bones J, Karger BL (2011) Rapid high-resolution characterization of functionally important monoclonal antibody N-glycans by capillary electrophoresis. Anal Chem 83(13):5329–5336.

  94. Tarentino AL, Plummer TH Jr (1994) Enzymatic deglycosylation of asparagine-linked glycans: purification, properties, and specificity of oligosaccharide-cleaving enzymes from Flavobacterium meningosepticum. Methods Enzymol 230:44–57

  95. Thomann M, Reckermann K, Reusch D, Prasser J, Tejada ML (2016) Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol 73:69–75.

  96. Tommasone S, Allabush F, Tagger YK, Norman J, Kopf M, Tucker JHR, Mendes PM (2019) The challenges of glycan recognition with natural and artificial receptors. Chem Soc Rev 48(22):5488–5505.

  97. Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen P, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK (2018) FcgammaRIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils. Front Immunol 9:3124.

  98. van de Bovenkamp FS, Hafkenscheid L, Rispens T, Rombouts Y (2016) The emerging importance of IgG fab glycosylation in immunity. J Immunol 196(4):1435–1441.

  99. Varki A (2001) N-glycolylneuraminic acid deficiency in humans. Biochimie 83(7):615–622

  100. Wang EQ, Bukowski JF, Yunis C, Shear CL, Ridker PM, Schwartz PF, Baltrukonis D (2019) Assessing the potential risk of cross-reactivity between anti-bococizumab antibodies and other anti-PCSK9 monoclonal antibodies. Biodrugs 33(5):571–579.

  101. Wang Q, Chung CY, Chough S, Betenbaugh MJ (2018) Antibody glycoengineering strategies in mammalian cells. Biotechnol Bioeng 115(6):1378–1393.

  102. Wolf RA, Marx ME, Szalaj L, Kuper JJ, Cavanaugh PF (2015) Allergic/infusion reactions reported with cetuximab and rituximab. World Allergy Organ 8(Suppl 1):A82–A82

  103. Wolfert MA, Boons GJ (2013) Adaptive immune activation: glycosylation does matter. Nat Chem Biol 9(12):776–784.

  104. Wright A, Morrison SL (1998) Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 160(7):3393–3402

  105. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87(5):614–622.

  106. Yang J, Primack R, Frohn M, Wang W, Luan P, Retter MW, Flynn GC (2015a) Impact of glycation on antibody clearance. AAPS J 17(1):237–244.

  107. Yang X, Kim SM, Ruzanski R, Chen Y, Moses S, Ling WL, Li X, Wang SC, Li H, Ambrogelly A, Richardson D, Shameem M (2016) Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies. MAbs 8(4):706–717.

  108. Yang Z, Wang S, Halim A, Schulz MA, Frodin M, Rahman SH, Vester-Christensen MB, Behrens C, Kristensen C, Vakhrushev SY, Bennett EP, Wandall HH, Clausen H (2015b) Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat Biotechnol 33(8):842–844.

  109. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R (2012) Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 4(4):475–487.

  110. Yu YQ, Gilar M, Kaska J, Gebler JC (2005) A rapid sample preparation method for mass spectrometric characterization of N-linked glycans. Rapid Commun Mass Spectrom 19(16):2331–2336.

  111. Zhang L, Luo S, Zhang B (2016a) Glycan analysis of therapeutic glycoproteins. MAbs 8(2):205–215.

  112. Zhang L, Luo S, Zhang B (2016b) The use of lectin microarray for assessing glycosylation of therapeutic proteins. MAbs 8(3):524–535.

  113. Zhang N, Liu L, Dumitru CD, Cummings NRH, Cukan M, Jiang Y, Yuan L, Fang L, Mitchell T, Mallem MR (2011) Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. Mabs 3(3):289–298

  114. Zhang Q, Gimeno A, Santana D, Wang Z, Valdes-Balbin Y, Rodriguez-Noda LM, Hansen T, Kong L, Shen M, Overkleeft HS, Verez-Bencomo V, van der Marel GA, Jimenez-Barbero J, Chiodo F, Codee JDC (2019a) Synthetic, zwitterionic Sp1 oligosaccharides adopt a helical structure crucial for antibody interaction. ACS Cent Sci 5(8):1407–1416.

  115. Zhang Z, Shah B, Richardson J (2019b) Impact of fc N-glycan sialylation on IgG structure. MAbs 11(8):1381–1390.

  116. Zhao M, Wang J, Luo M, Luo H, Zhao M, Han L, Zhang M, Yang H, Xie Y, Jiang H, Feng L, Lu H, Zhu J (2018) Rapid development of stable transgene CHO cell lines by CRISPR/Cas9-mediated site-specific integration into C12orf35. Appl Microbiol Biotechnol 102(14):6105–6117.

  117. Zhou Q, Qiu H (2019) The mechanistic impact of N-glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins. J Pharm Sci 108(4):1366–1377.

  118. Zong HF, Han L, Ding K, Wang JX, Sun T, Zhang XY, Cagliero C, Jiang H, Xie YQ, Xu JR, Zhang BH, Zhu JW (2017) Producing defucosylated antibodies with enhanced in vitro antibody-dependent cellular cytotoxicity via FUT8 knockout CHO-S cells. Eng Life Sci 17(7):801–808.

  119. Zou G, Ochiai H, Huang W, Yang Q, Li C, Wang LX (2011) Chemoenzymatic synthesis and Fcgamma receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcgammaIIIa receptor. J Am Chem Soc 133(46):18975–18991.

Download references

Author information

Correspondence to Huili Lu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wang, Z., Zhu, J. & Lu, H. Antibody glycosylation: impact on antibody drug characteristics and quality control. Appl Microbiol Biotechnol (2020).

Download citation


  • Glycosylation
  • Antibodies
  • Pharmacokinetics
  • Analysis